Issue : Clinical Pharmacist, 2011
Sort by: Newest first Oldest first A-Z Z-A
-
New antiretroviral launched in the UK
Rilpivirine, a?new non-nucleoside reverse transcriptase inhibitor, has been launched in the UK for the management of HIV-1 infection in treatment-naive patients.
-
Decriminalisation of single dispensing errors comes one step closer
Decriminalisation of single dispensing errors has come a step closer with the tabling of an amendment to the Health and Social Care Bill.
-
Review antibiotic treatment within 48 hours, DH guidance recommends
Antibiotic treatment for hospital inpatients should be reviewed within 48 hours of being started, and an ongoing management plan documented clearly in the medical notes, according to recently published Department of Health guidance.
-
High-intensity regimen improves survival for B-cell lymphoma, but toxicity concerns raised
Patients with diffuse large B-cell lymphoma have better treatment success when given a new high-intensity anticancer regimen, compared with the current UK standard of care, suggests research published in The Lancet (2011;378:1858).
-
Rivaroxaban improves CV outcomes after ACS
Adding rivaroxaban to standard treatment with aspirin and a thienopyridine can improve cardiovascular outcomes for patients with acute coronary syndrome (ACS), according to research published online in the New England Journal of Medicine (13 November 2011).
-
NHS?pharmacist numbers hold steady while vacancy rates fall
NHS pharmacist numbers in England and Wales remained fairly constant in the period from May 2010 to May 2011, according to figures from this year’s national NHS pharmacy staffing establishment and vacancy survey.
-
What information should we use? (David Gibson) Subscription
Senior clinical pharmacist (medical admissions) at Darlington Memorial Hospital
-
Ways clinical pharmacists can add value in intermediate care settings Subscription
Patients in intermediate care are “low risk” with regard to medicines issues so they have little need for a clinical pharmacy service, right? Ateam of pharmacists from Harrow wish to argue otherwise
-
Strikes, QIPP, job uncertainty. What next? Subscription
It seems like the theme of this year has been cuts. For NHS pharmacists these are being felt personally and professionally (pay freezes, pension proposals and the on-call debacle spring to mind).
